LoRusso PM - Search Results

1

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P. LoRusso PM, et al. Clin Cancer Res. 2012 May 15;18(10):2954-63. doi: 10.1158/1078-0432.CCR-11-2873. Epub 2012 Mar 6. Clin Cancer Res. 2012. PMID: 22394984 Free PMC article. Clinical Trial.

2

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.

Zalupski MM, Philip PA, LoRusso P, Shields AF. Zalupski MM, et al. Cancer Chemother Pharmacol. 1997;40(3):225-7. doi: 10.1007/s002800050650. Cancer Chemother Pharmacol. 1997. PMID: 9219505 Clinical Trial.

3

Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.

Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Foster BJ, et al. Among authors: lorusso pm. Clin Cancer Res. 1997 Nov;3(11):2047-53. Clin Cancer Res. 1997. PMID: 9815596

4

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L. LoRusso P, et al. Clin Cancer Res. 1995 Dec;1(12):1487-93. Clin Cancer Res. 1995. PMID: 9815948 Clinical Trial.

5

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Among authors: lorusso pm. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

6

Phase II study of CI-958 in colorectal cancer.

Shields AF, Philip PA, LoRusso PM, Ferris AM, Zalupski MM. Shields AF, et al. Among authors: lorusso pm. Cancer Chemother Pharmacol. 1999;43(2):162-4. doi: 10.1007/s002800050878. Cancer Chemother Pharmacol. 1999. PMID: 9923823 Clinical Trial.

7

Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.

Keyes KA, Albella B, LoRusso PM, Bueren JA, Parchment RE. Keyes KA, et al. Among authors: lorusso pm. Clin Cancer Res. 2000 Jun;6(6):2474-81. Clin Cancer Res. 2000. PMID: 10873102

8

Phase I pharmacokinetic study of the novel antitumor agent SR233377.

LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. LoRusso PM, et al. Clin Cancer Res. 2000 Aug;6(8):3088-94. Clin Cancer Res. 2000. PMID: 10955788 Clinical Trial.

9

Chronic oral administration of CI-994: a phase 1 study.

Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM. Prakash S, et al. Among authors: lorusso pm. Invest New Drugs. 2001;19(1):1-11. doi: 10.1023/a:1006489328324. Invest New Drugs. 2001. PMID: 11291827 Clinical Trial.

10

The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.

Ding Z, Parchment RE, LoRusso PM, Zhou JY, Li J, Lawrence TS, Sun Y, Wu GS. Ding Z, et al. Among authors: lorusso pm. Clin Cancer Res. 2001 Nov;7(11):3336-42. Clin Cancer Res. 2001. PMID: 11705845

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

345 results

Search Page

Filters